InspireMD grants restricted stock to new non-executive employee

MIAMI, Sept. 04, 2026 /CourierPR/ -- InspireMD, Inc., the developer of the CGuard™ Prime carotid stent system for stroke prevention, has announced the grant of 23,764 shares of restricted stock to a new non-executive employee. The inducement grants, approved by the company's Compensation Committee, are part of a special plan designed to attract and retain key talent, in compliance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants were issued under the company’s 2024 Inducement Plan, a mechanism exclusively used for the grant of equity awards to new employees and those who have been away from the company for a period. The shares will vest over three years, with portions becoming eligible for release in installments on specified dates. Specifically, 11,264 shares will vest in three equal installments on January 14, 2027, 2028, and 2029, while 12,000 shares will vest in two equal installments on January 20, 2027, and 2028. An additional 500 shares will vest in three equal installments on June 12, 2027, 2028, and 2029, contingent upon the recipient’s continued employment with the company.

InspireMD’s focus remains on leveraging its proprietary MicroNet™ mesh technology to establish its carotid stent systems as the industry standard. The company’s common stock is traded on the Nasdaq under the ticker symbol NSPR. InspireMD regularly updates investors through its website, which is a key source of information for stakeholders.

The company has faced challenges in the past, including a voluntary U.S. recall of its CGuard Prime 135 cm delivery system. This recall has involved significant costs and operational disruptions, potentially impacting sales and customer relationships. Additionally, InspireMD continues to navigate a complex landscape of regulatory compliance, financial challenges, and competitive pressures, all while striving to develop and commercialize its innovative products.

Forward-looking statements included in the press release caution investors about potential risks and uncertainties, including the ongoing impacts of the CGuard recall, the company’s financial performance, and regulatory and operational challenges. InspireMD’s ability to continue as a going concern and its reliance on future capital raises are also highlighted as critical areas of concern.